ArticleMolecular and cellular pediatrics2025
Serum bile acid profiles in pediatric gastrointestinal, hepatic and biliary diseases.
Article in Molecular and cellular pediatrics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND AND
aimsAltered bile acids (BA) are key drivers of hepatic disorders and beyond. The breakdown of BA profiles could serve as advanced biomarkers, but data in pediatric patients is scarce. In this work we retrospectively analyzed routine BA profiles of various pediatric gastrointestinal, hepatic and biliary diseases.
methodsRoutine tandem mass spectrometry derived serum BA profiles from a ten-year period (2014–2024) of a pediatric tertiary care center were analyzed. First, guidance values for 15 bile acid components for six age groups were established. Next, BA profiles were examined across gastrointestinal, hepatic and biliary diseases.
resultsA total of 1906 bile acid profiles from n = 524 patients were analyzed, with 1341 (n = 167) profiles from patients with gastrointestinal, 222 (n = 143) with hepatic, and 269 (n = 159) with biliary diseases. Total primary BA were found to be higher in younger compared to older children, with an increase in secondary BA with age. Significant BA alterations were observed in patients with certain hepatic and biliary diseases including an increased primary to secondary BA ratio, a reduced proportion of unconjugated BA and increased glycine- to taurine-conjugation ratio.
conclusionWe provide guidance BA profile values for different pediatric age groups and an overview of altered BA profiles in gastrointestinal, hepatic and biliary diseases. This work emphasizes the potential of BA profiles as a diagnostic tool and could serve as a guide for clinical interpretation and as framework for future studies in the field.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.